Hepatocellular carcinoma to renal cell carcinoma metastasis: a rare phe--nomenon with diagnostic challenges
To the Editor: The coexistence of two or more synchronous or metat t chronous malignancies in the same patient is not uncommon. 1 Tumort tottumor metastasis is, however, a rarer phenomenon. 1, 2 Probably, the first case reported in the literature was by Berent in 1902 , in which squamous cell carcinoma of the jaw metastasized to renal cell carcinot t ma. 3 Rabson et al found 50 reported cases of cancerttotcancer metastasis in 1954. 4 Petraki et al found 150 ret t ported cases of tumorttottumor met t tastasis in 2003. 1 We report a case of hepatocellular carcinoma metastat t sized into renal cell carcinoma.
A 70tyeartold nontlocal woman presented with intermittent abdomit t nal pain. Four months prior to current presentation the patient was diagnosed with hepatocellular carcinoma (HCC) in her home country and received one cycle of chemotherapy. The patient det t cided to travel abroad to complete her treatment in our hospital. Computed tomography showed a right hepatic lobe mass that measured 7.7 cm with chemoembolization material and a cirrhotic liver (Figure 1) . The left kidney showed an upper pole nodt t ule that measured 3.5 cm (Figure 1) . The right kidney and adrenal glands were unremarkable. Alphatfetoprot t tein (AFP) was high (66.3 IU/mL). Clinical and radiological differential diagnoses included incidental renal cell carcinoma or metastatic hepatot t cellular carcinoma of the left kidney nodule. The patient was scheduled for frozen section of the left renal nodule and subsequent segmental resection of the hepatic mass.
We received segmental resection of the left kidney nodule that grossly measured 3.6 cm and showed a yelt t low mass with areas of hemorrhage. A frozen section showed histologic features of clear cell carcinoma cont t sistent with incidental renal cell carcinoma (RCC) of the left kidt t ney. Subsequent permanent sect t tions confirmed the frozen section diagnosis of lowtgrade conventional renal clear cell carcinoma. However, a smaller granular eosinophilic nodt t ule (measuring 2.5 mm) was found within the renal cell carcinoma nodt t ule (Figure 2) . This nodule showed a highly pleomorphic eosinophilic neoplasm with focal trabecular and pseudoacinar growth pattern lined by endothelial cells. High mitotic activity with atypical mitotic figures was present (Figure 2) . Histologic differential diagnoses of the smaller The liver mass was not resected because the patient developed severe lifetthreatening intraoperative bleedt t ing and received several blood transt t fusions. The patient died two days after surgery because of uncontrolled hemorrhage. Because of social, ethical and religious restrains, postmortem examinations are not performed in our region, and therefore no autopsy study was carried out on the patient.
Tumorttottumor metastasis can occur in patients with synchronous or metachronous simultaneous primaries. 1t4 This phenomenon is infrequent, but probably more comt t mon than previously reported.
1,2
The receiving host neoplasm could be benign or malignant. The most common receiving malignancy is renal cell carcinoma. 1, 2, 4 Other host neoplasms include sarcomas, met t ningiomas, thyroid neoplasms and pituitary adenomas. 1, 2, 4 The most common donor neoplasm is primary lung carcinoma followed by breast, prostate and thyroid carcinomas. 1, 2, 4 Other metastatic donor malignant t cies reported included squamous cell carcinoma of the head and neck region, melanoma, and colonic and gastric carcinomas, but HCC has not been previously reported. The definition of one primary malignancy metastasizing to another primary neoplasm within the same patient should be based on certain criteria. Campbell et al 5 proposed a set of criteria for the diagnosis of tut t mort tottumor metastasis which int t clude: 1) the existence of more than one primary tumor in the patient, 2) the recipient tumor must be a true neoplasm, 3) the donor tumor must be a true metastasis (direct contigut t ous spreading or collision tumor is not acceptable), and 4) lymphatic metastasis should be excluded. The reason why RCC was the most comt t mon host malignancy is unclear. Several theories have attempted to explain why nontmetastasizing early renal cell carcinoma is the favorite host tumor in cancerttotcancer met t tastasis.
1,2 These mechanical and biochemical factors include: 1) the kidneys are vascular organs with abundant blood supply, 2) RCC is a very vascular neoplasm, 3) RCC provides a lipid and glycogen rich environment for tumor growth, 4) angiogenic or hormonal secretion by RCC cells, and 5) early lowtgrade RCC provides an aerobic oxygent rich metabolic environment suitable for tumor growth. These hypotheses need validation by more probing studies that may shed light into the behavior and underlying pathogent t esis of metastasizing cancers.
It is sometimes difficult to dist t tinguish between renal cell carcit t noma and HCC, particularly clear cell types. Clues to HCC might include the presence of focal trat t becular and pseudoglandular growth pattern. 6 The presence of bile pigt t ments and Mallory bodies are helpt t ful, but they are not always present particularly in high grade HCC. 6, 7 Immunohistochemistry with a small panel of HepPart1 and CD10 can help. 6, 7 HepPart1 is the most specific marker for hepatic differentiation. 6, 7 It can be patchy and variable somet t times, but shows characteristic grant t ular cytoplasmic staining. 6 HepPart1 is almost always negative in RCC. 6, 7 CD10 is a good marker for RCC, but not specific. It can be positive in HCC, but usually shows a canalicular pattern in the trabecular areas as opt t posed to the brisk membrane staint t ing in RCC. 6, 7 AFP is not specific and can be negative in HCC. 6 In conclusion, tumorttottumor metastasis is an infrequent, but not a rare event. HCCttotRCC metast t tasis is rare and can be considered as one of the rarest cancerttotcant t cer metastasis. Sometimes, it can be morphologically difficult to distint t guish between HCC and RCC. This could present diagnostic challenges to the pathologist, particularly on the frozen section. Simple immunot t histochemistry panel of HepPart1 and CD10 is helpful to distinguish between the two neoplasms. 
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CD123 monoclonal anti--body in myelodysplastic syndrome
To the Editor: CD123 monoclot t nal antibody is an IL3Ra antirecept t tor useful in the diagnosis of hairy cell leukemia. 1 It is widely used to recognize minimal residual disease (MRD) in treated acute myeloid leukemia (AML). We studied 20 pat t tients with a diagnosis of myelodyst t plastic syndrome (MDS). The most prominent clinical sign was leukot t penia with variable lymphocytosis, and disease evolution of more than a year. Patient ages ranged between 32 to 81 years, and included 11 women and 9 men. Laboratory bone mart t row findings were consistent with hypercellular and heteromorphous cytology with erythroid dysplasia and the presence of PelgertHuett anomaly, with increased intermedit t ate forms, immature myeloid series and macroplatelets. Serum iron and ferritin were measured and one marrow iron and biopsy were obtained. Flow cytometry monot t clonal antibodies used included CD34 + CD123, CD38 + CD123, CD34 + CD117, CD34 + CD38, CD123, and p53 and Bcl2. These monoclonal combinations were studied to determine the presence of leukemic stem cells (LSC). The analysis showed evidence of CD123 in 12 patients, with more than 20% (range, 22%t66%). In the remaint t ing 8 patients, CD123 was less than 20% (range, 6%t16%). The CD34 + CD117 combination findings corresponded with 16%t56%s. The patient samples were also marked with CD38, with a presence of 39%t82%, indicating cellular activat t tion. When compared with CD34 + CD123, the range was 20%t95%. Taking into account total positivity, all our patients had an increased presence of CD123, in addition to CD34 and CD117. Eleven (n=11) patients presented with alterat t tions in p53, and 14 had the prest t ence BCL2 oncogene. Patients with more than 20% CD123 were treated with antitmethylation drugs. Our conclusions indicate that the use of CD123 with other immaturity markers corresponds with MDS and relates to the presence of LSC. The use of this marker may help in early identification and treatment of cases with higher potential for leut t kemic transformation. Limited but similar findings have been reported about the value of CD123, under comparable conditions. 
